top of page
All Posts
August 1 Rivaroxaban – Sandoz’ claim for profit disgorgement
Bayer’s Xarelto (rivaroxaban) blood-thinning agent has been the subject of patent disputes in many jurisdictions, including Australia....
Wayne Condon
Aug 32 min read
Early Notification of Generic Medicine Applications in Australia – Quo Vadis ?
In March this year the Office of the United States Trade Representative ( USTR ) published the 2025 National Trade Estimate Report on...
Wayne Condon
Jul 75 min read
A second round of Stelara patents revoked in Australia
In an unusual move, on 9 June three Australian innovation patents claiming the use of Stelara to treat ulcerative colitis were revoked...
Wayne Condon
Jun 231 min read
bottom of page